We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Test for HPVs Uses Standard Diagnostic Equipment

By Biotechdaily staff writers
Posted on 19 Nov 2007
A DNA-based diagnostic test for human papillomavirus (HPV) uses standard molecular diagnostic equipment found in most commercial laboratories. The HPV DNA test complements a HPV blood test being developed to detect the presence of antibodies produced by cancer-causing HPV types.

There are some 100 types of HPV; however, only about 7-15 HPV-types cause most cervical cancers. Grant Life Sciences, a developer of diagnostic testing systems, believes that a blood-based test to detect precancerous evidence and cancer of the cervix is the preferred test-methodology to address the needs of the developing world. Molecular (DNA) testing is currently the approved test protocol in both the United States and Europe to identify the presence of different subtypes of HPV in the cervix.

An agreement has been signed by Grant Life Sciences, Inc. (Salt Lake, UT, USA) and Alphagenics Diaco Biotechnologies S.r.l. (Trieste, Italy) to exclusively in-license the manufacturing and marketing rights to the Alphagenics' molecular diagnostic test for human papillomaviruses (HPVs) in China and the United States and non-exclusively in all other countries.

The introduction of the Alphagenics HPV test not only will allow commercial laboratories to provide molecular testing but will also complement the current introduction of vaccines against HPVs, according to Dr. Hun-Chi Lin, president and chief scientist, Grant Life Sciences.

In addition, Dr. Lin said that the Alphagenics test could be used in the current gynecologic regimen to help qualify Pap test results in the case of ambiguous readings, at a cost less than the currently approved molecular test. Grant Life expects to launch the Alphagenics HPV DNA-based test in the Asian and Indian markets during the first quarter of 2008 as an Analyte-Specific Reagent (ASR) to reference laboratories.

Alphagenics Diaco Biotechnologies is one of the most specialized companies in Italy in the use of technical innovation in molecular biology for the production of kits for clinical and research use in oncology, bacteriology, virology, and mycology.

Grant Life Sciences engages in research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.


Related Links:
Grant Life Sciences
Alphagenics Diaco Biotechnologies S.r.l.

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Alcohol Testing Device
Dräger Alcotest 7000

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
19 Nov 2007  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
19 Nov 2007  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
19 Nov 2007  |   BioResearch